Drug Profile
CC 95775
Alternative Names: CC 95775; FT1101Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Developer Celgene Corporation; FORMA Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in France (PO, Capsule)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Spain (PO, Capsule)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in France (PO, Capsule)